Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide.
Source
Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
Abstract
BACKGROUND AND PURPOSE:
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide displaying anti-inflammatory and analgesic actions. To investigate the molecular mechanism responsible for these effects, the ability of PEA and of pain-inducing stimuli such as capsaicin (CAP) or bradykinin (BK) to influence intracellular calcium concentrations ([Ca²⁺](i)) in peripheral sensory neurons, has been assessed in the present study. The potential involvement of the transcription factor PPARα and of TRPV1 channels in PEA-induced effects was also studied.
EXPERIMENTAL APPROACH:
[Ca²⁺](i) was evaluated by single-cell microfluorimetry in differentiated F11 cells. Activation of TRPV1 channels was assessed by imaging and patch-clamp techniques in CHO cells transiently-transfected with rat TRPV1 cDNA.KEY RESULTS:
In F11 cells, PEA (1-30 μM) dose-dependently increased [Ca²⁺](i). The TRPV1 antagonists capsazepine (1 μM) and SB-366791 (1 μM), as well as the PPARα antagonist GW-6471 (10 μM), inhibited PEA-induced [Ca²⁺](i) increase; blockers of cannabinoid receptors were ineffective. PEA activated TRPV1 channels heterologously expressed in CHO cells; this effect appeared to be mediated at least in part by PPARα. When compared with CAP, PEA showed similar potency and lower efficacy, and caused stronger TRPV1 currents desensitization. Sub-effective PEA concentrations, closer to those found in vivo, counteracted CAP- and BK-induced [Ca²⁺](i) transients, as well as CAP-induced TRPV1 activation.
CONCLUSIONS AND IMPLICATIONS:
Activation of PPARα and TRPV1 channels, rather than of cannabinoid receptors, largely mediate PEA-induced [Ca²⁺](i) transients in sensory neurons. Differential TRPV1 activation and desensitization by CAP and PEA might contribute to their distinct pharmacological profile, possibly translating into potentially relevant clinical differences.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
- PMID:
- 23083124
- [PubMed – indexed for MEDLINE]
- PMCID:
- PMC3596648
- [Available on 2014/3/1]
Publication Types, MeSH Terms, Substances
Publication Types
MeSH Terms
- Action Potentials/drug effects
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/antagonists & inhibitors
- Anti-Inflammatory Agents, Non-Steroidal/pharmacology*
- CHO Cells
- Calcium Signaling/drug effects
- Cell Line
- Cricetinae
- Cricetulus
- Drug Antagonism
- Endocannabinoids/antagonists & inhibitors
- Endocannabinoids/pharmacology*
- Ethanolamines/antagonists & inhibitors
- Ethanolamines/pharmacology*
- Membrane Transport Modulators/antagonists & inhibitors
- Membrane Transport Modulators/pharmacology
- Mice
- Nerve Tissue Proteins/agonists*
- Nerve Tissue Proteins/antagonists & inhibitors
- Nerve Tissue Proteins/genetics
- Nerve Tissue Proteins/metabolism
- PPAR alpha/agonists*
- PPAR alpha/antagonists & inhibitors
- PPAR alpha/metabolism
- Palmitic Acids/antagonists & inhibitors
- Palmitic Acids/pharmacology*
- Rats
- Recombinant Proteins/agonists
- Recombinant Proteins/antagonists & inhibitors
- Recombinant Proteins/metabolism
- Sensory Receptor Cells/cytology
- Sensory Receptor Cells/drug effects*
- Sensory Receptor Cells/metabolism
- TRPV Cation Channels/agonists*
- TRPV Cation Channels/antagonists & inhibitors
- TRPV Cation Channels/genetics
- TRPV Cation Channels/metabolism
- Tachyphylaxis*